# COVID-19 Study to Evaluate Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVID-19 Adult and Adolescent Patients Without Risk Factors for Progression to Severe Disease

> **NCT05081388** · PHASE1,PHASE2 · TERMINATED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 25 (actual)

## Conditions studied

- SARS-CoV-2

## Interventions

- **DRUG:** REGN14256
- **DRUG:** imdevimab
- **DRUG:** casirivimab + imdevimab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05081388
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-11-08
- **Primary completion:** 2022-06-30
- **Final completion:** 2022-06-30
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** Sponsor Decision
- **Last updated:** 2025-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05081388

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05081388, "COVID-19 Study to Evaluate Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVID-19 Adult and Adolescent Patients Without Risk Factors for Progression to Severe Disease". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05081388. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*